Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
AnaptysBio (ANAB) has announced it will host an investor call and live webcast on February 12, 2025, at 8:30 AM ET to present top-line data from its global Phase 2b RENOIR clinical trial. The trial evaluates rosnilimab, a PD-1+ T cells depleter and agonist, for the treatment of moderate-to-severe rheumatoid arthritis. The data will be released through a morning press release and discussed during the webcast, which will be accessible via the company's investor relations website. A replay will remain available for at least 30 days after the event.
AnaptysBio (ANAB) ha annunciato che ospiterà una chiamata per gli investitori e una trasmissione in diretta il 12 febbraio 2025, alle 8:30 AM ET, per presentare i dati preliminari del suo trial clinico globale Phase 2b RENOIR. Lo studio valuta rosnilimab, un depletore di cellule T PD-1+ e agonista, per il trattamento dell'artrite reumatoide da moderata a grave. I dati saranno rilasciati tramite un comunicato stampa mattutino e discussi durante la trasmissione web, che sarà accessibile tramite il sito web delle relazioni con gli investitori della società. Una registrazione sarà disponibile per almeno 30 giorni dopo l'evento.
AnaptysBio (ANAB) ha anunciado que llevará a cabo una llamada para inversores y una transmisión en vivo el 12 de febrero de 2025, a las 8:30 AM ET para presentar los datos preliminares de su ensayo clínico global Phase 2b RENOIR. El ensayo evalúa rosnilimab, un depletador de células T PD-1+ y agonista, para el tratamiento de la artritis reumatoide de moderada a grave. Los datos se publicarán a través de un comunicado de prensa matutino y se discutirán durante la transmisión, que será accesible a través del sitio web de relaciones con inversores de la compañía. Una repetición estará disponible durante al menos 30 días después del evento.
AnaptysBio (ANAB)는 2025년 2월 12일 오전 8시 30분 ET에 투자자 전화회의와 생중계를 개최한다고 발표했습니다. 이 회의에서는 글로벌 2상 RENOIR 임상 시험의 주요 데이터를 발표할 예정입니다. 이 시험은 중등도에서 중증의 류마티스 관절염 치료를 위해 PD-1+ T 세포 소모 및 작용제인 rosnilimab를 평가합니다. 데이터는 아침 보도자료를 통해 공개되며, 기업의 투자자 관계 웹사이트를 통해 생중계 중 논의될 것입니다. 이벤트 후 최소 30일 동안 다시 보기 기능이 제공됩니다.
AnaptysBio (ANAB) a annoncé qu'il tiendrait un appel aux investisseurs et un webinaire en direct le 12 février 2025 à 8h30 ET pour présenter les données préliminaires de son essai clinique mondial Phase 2b RENOIR. L'essai évalue rosnilimab, un dépleteur de cellules T PD-1+ et agoniste, pour le traitement de l'arthrite rhumatoïde modérée à sévère. Les données seront diffusées par le biais d'un communiqué de presse matinal et discutées lors du webinaire, accessible via le site web des relations investisseurs de l'entreprise. Une rediffusion sera disponible pendant au moins 30 jours après l'événement.
AnaptysBio (ANAB) hat angekündigt, am 12. Februar 2025 um 8:30 Uhr ET eine Telefonkonferenz für Investoren und ein Live-Webcast abzuhalten, um die wichtigsten Daten aus seiner globalen Phase 2b RENOIR-Studie vorzustellen. Die Studie bewertet rosnilimab, einen PD-1+ T-Zell-Depletor und Agonisten, zur Behandlung von moderater bis schwerer rheumatoider Arthritis. Die Daten werden über eine morgendliche Pressemitteilung veröffentlicht und während des Webcasts diskutiert, der über die Investor-Relations-Website des Unternehmens zugänglich ist. Eine Wiederholung wird für mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
A live webcast of the call will be available on the Anaptys website at: https://ir.anaptysbio.com/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When will AnaptysBio (ANAB) release Phase 2b RENOIR trial results for rosnilimab?
What is the purpose of AnaptysBio's RENOIR trial for rosnilimab?
How can investors access ANAB's rosnilimab Phase 2b data presentation?
How long will the replay of ANAB's rosnilimab Phase 2b data presentation be available?
